RSV information for you as a healthcare worker


Prevention of RSV through Immunization with Monoclonal Antibodies in Young Children during Their First Year: Communication, Information and Broad monitoring.

Click on the quick links to jump to the following information:

Collaboration between General Practitioners and Pediatricians

In collaboration with general practitioners (Domus Medica and SSMG) , VVOG, Zorg en Gezondheid, paediatricians (BAoP), we worked on a communication regarding this campaign. We will keep monitoring the situation closely and update you on developments.

We aim to provide clear information based on confirmed data and clarify any uncertainties. This information has been compiled and streamlined from various official sources, reflecting the most recent and confirmed data available at the time of publication. We ask you not to distribute unverified information and to contact us with any questions.

Commitments of the RSV prevention Task Force:

  • We take on a connecting, coordinating, and quality-assuring role between various stakeholders, the public, different governments, and industry. The RSV Prevention Task Force is formed out of various stakeholders. Your questions can be addressed via info@baop.be.
  • We provide transparent, streamlined information, communication and materials for both healthcare professionals and parents. All tis information is to be found in 3 languages on this site.
  • We have launched surveys in which you can participate.
  • We will monitor the communication, quality, safety, and workload of this process and consider your concerns. This includes advocating for your interests and ensuring that parents do not miss out on reimbursement and end up with a high bill.


The RSV prevention Task Force is not:

  • Responsible for relevant regulations, reimbursement modalities, though we will continue to monitor critically.
  • Directly accessible to parents, and we kindly ask that communication with parents goes through you as a healthcare professional.
  • Responsible for the practical organization of immunization for infants or vaccination of pregnant women. This is up to you as a healthcare professional/hospital/private practice to organize in a way that suits your target group, region, and existing collaborations.

Protective Measures

Two protective measures

To prevent severe RSV infection and hospitalization in infants, two protective measures will be available in Belgium. We advise you, as a healthcare professional, to inform your patients about these measures to protect the youngest members of our society: Beyfortus° & Abrysvo°. 

Nirsevimab (Beyfortus°): 

All newborns born during the RSV season are eligible for reimbursement of Beyfortus °. However, immunization is best performed from September 1, from the day after birth and before discharge from maternity. This is in accordance with the RIZIV/INAMI regulations. 

Catch-up group (children born between 16th March and 30th September 2026; with the possibility to extend till the end of October and depending on the evolution of the RSV season)

Prematures residing at NICU (<13 months old and born before March 16, 2026) that did not yet receive immunization with nirsevimab during the 1st year of life are in line with the provisions of the compensation conditions as a catch-up group. Since these premature babies most likely did not come into contact with the RSV virus during the 2025-2026 RSV season, 2026-2027 is considered their first ‘real ’ RSV season. (cf. agreement RIZIV / INAMI).

The reimbursement of Beyfortus° for vulnerable children

The reimbursement of Beyfortus° for vulnerable children during their second season and children undergoing cardiac surgery has been approved.

 CBIP | Remboursement   Annexe A - Formulaire de demande 

 BCFI | Terugbetaling  Bijlage A - Aanvraagformulier

Maternal vaccination (Abrysvo°):

Pregnant women with an expected delivery date during the RSV season:Vaccination with Abrysvo™ between the 28th and 36th weeks of pregnancy and with an expected delivery date during the RSV season 2026-2027.

More information


Technical Product Information and Inclusion Criteria

We offer you objective technical information. It is up to you, as a healthcare professional, to assess with the parents, considering their unique context, which option is most suitable for a specific family.

1. ABRYSVO™

Inclusion Criteria:

  • Any pregnant woman with an expected delivery date during the RSV season.
  • Vaccination between the 28th and 36th weeks of pregnancy (be careful not to vaccinate too early to ensure protection lasts for the newborn).
  • If the maternal vaccine is chosen, the newborn is no longer eligible for reimbursement of nirsevimab (Beyfortus™). See exceptions in the HGR December 2023, No. 9760.
  • The woman must have a valid Belgian National Register number.
  • A prescription from a general practitioner or gynecologist is required.

The Product:

  • Name: Abrysvo™.
  • A vaccine
  • A single intramuscular injection in the pregnant woman between the 28th and 36th weeks of pregnancy, as described in the HGR December 2023, No. 9760.
  • The produced antibodies are passed through the placenta.
  • Provides protection for 5 to 6 months after birth.
  • Reduces the risk of severe RSV infection, including the need for hospitalization.
  • It is almost fully reimbursed, costing parents:
    • €12
    • €8 with increased reimbursement.
  • General non-pharmacological preventive advice to prevent RSV and other respiratory infections remains applicable.


2. Nirsevimab (Beyfortus™)

Inclusion Criteria:

  • Any child born born from 1st October 2025 till the end of the RSV season.
  • The child must have a valid Belgian National Register number.
  • Reimbursement applies only if the mother did NOT receive the RSV vaccine Abrysvo™ during pregnancy. As described in the HGR December 2023, No. 9760.
  • Approval must be granted by the advisory physician via Chapter 4, either electronically (via EMD or CIVARS) or via a paper document. Exceptions are described in the HGR guidelines (December 2023, No. 9760).

The Product:

  • Name: Nirsevimab (Beyfortus™)  (package insert)
  • Not a vaccine but a monoclonal antibody, so it should not be referred to as a vaccine.
  • A single intramuscular injection per season.
  • Provides protection for 5 to 6 months.
  • Reduces the risk of severe RSV infection, including the need for hospitalization.
  • Has a good safety profile
  • Dosage:
    • <5 kg: 50 mg intramuscularly.
    • >5 kg: 100 mg intramuscularly.
  • Storage: (important to inform parents if they pick up the product themselves from the pharmacy)
    • Store in the refrigerator (between 2° and - 8°)
    • Do not freeze.
    • Maximum 48 hours between 20-25 °C.
    • Do not shake.
    • Do not expose to heat.
    • Keep the pre-filled syringe in the outer packaging to protect it from light.
  • It is almost fully reimbursed, costing parents:
    • €12
    • €8 with increased reimbursement.
  • General non-pharmacological preventive advice to prevent RSV and other respiratory infections remains applicable.


Practical Administration:

  • Can be administered to newborns during their stay in the maternity ward (e.g., during neonatal screening), in a hospital paediatrics consultation, or in a private practice consultation with a general practitioner or paediatrician.
  • Concurrent administration with vaccines: 
    • As nirsevimab is a monoclonal antibody with passive immunization specifically against RSV, it is not expected to interfere with the active immune response to co-administered vaccines.
    • There is limited experience with concurrent administration of vaccines. When nirsevimab was given with routine childhood vaccines during clinical trials, the safety and reactogenicity profile of the concurrent regimen was similar to that of the vaccines given alone. Nirsevimab can be given concurrently with childhood vaccines.
    • Nirsevimab should not be mixed with any vaccine in the same syringe or vial.
    • When administered concurrently with injectable vaccines, the injections should be given with separate syringes and at different injection sites.


In Flanders, Kind & Gezin informs but does not immunize. In Wallonia, ONE will both inform and immunize. In the East Cantons, Kaleido can also immunize the catch-up group.

Attention! Palivizumab (Synagis ®) ris not available anymore in Belgium and has been completely replaced by nirsevimab. 

Orders for Pharmacies

Information from Sanofi regarding orders for Beyfortus® 50 mg and Beyfortus® 100 mg.

Ordering method: Please specify the number of units (doses), not the number of boxes, when placing your order.

Verification: Kindly verify the correct distribution between 50 mg and 100 mg before placing your order.

Return policy: Due to the long shelf life of Beyfortus®, returns are not possible.

What can you do now?


  • Proactively contact your pregnant patients and / or the parents of your eligible paediatric patients and inform them of the possibilities.
  • You can start to contact the parents to make an appointment for the eligible vulnerable children.
  • For children born between March 16, 2025 and September 30th, 2026: if the parents choose nirsevimab (Beyfortis ™): plan an immunization appointment with them before or at the start of the RSV season (from September to early October). We refer to the reimbursement modalities of the RIZIV./INAMI (find Beyfortus and click on the eye for the modalities). Prepare the prescription with a refund request.
  • If they do not yet want an appointment, you can remind the parents, for example by using an obvious sticker
    • The stickers, available in French and Dutch, can be sent to you without charges: send an email to info@baop.be with your address and number of stickers wanted.
    • Print yourself ?: DAPPAZ stickers on A4 sticker sheets (24 stickers per sheet – D40MM- 5 sheets per pack, code LU-A4-24 (5)
  • Update your file: In the French speaking part it is necessary for health workers to register the Beyfortus in e-VaX.
  • Prepare the practical aspects of the immunization for your consultation (both intramurally and extramurally) with your colleagues. 
  • Don’t forget the policy regarding pain, anxiety, and stress prevention during painful procedures in infants.
  • Update your leaflet on general non-pharmacological RSV and bronchiolitis prevention and hand it to parents after immunization.

Data, procedures and extra information


Seasonal run (Sciensano)

The 2025-2026 RSV season officially ended on 16/03/2026.

The RSV season 2026-2027 starts on 01/10/2026.

Catch-up group

The children born between 16/03/2026 and 30/09/2026 can be immunized before the start of the RSV season or shortly after the start. (cf. RIZIV / INAMI: find Beyfortus and click on the eye for the modalities). Children born from 1st September can be immunized at the maternity ward. 

Administration should start in September 2025.

Prematures (born before 16th of March 2026)

Prematures are eligible for reimbursement for the season 2026-2027, if younger than 13 months and if they were not yet in contact with the RSV and didn’t receive monoclonals before. (confirmation RIZIV/INAMI, 13th June, 2025).

Refund procedure:

  • The procedure runs via Chapter 4 of the Electronic Medical Record (CIVARS) or by a paper document.
  • Only infants with a Belgian National Register number (RN) are eligible:Newborns, however, do not yet have these numbers during their stay in the maternity ward. Two confirmed options have been indicated by RIZIV-INAMI:
    • Either the application is made on paper, in the child's name, and the mutual insurance company will approve the application as soon as the RN is known.
      If the application cannot yet be made electronically (due to lack of an RN), a paper application can be made using the standard form (with the mother's and child's details). This can be entered into the system retroactively by the VI as soon as an RN is available (with retroactive approval).
    • Or electronically (via CIVARS or your software), but this can only be administratively processed once the applicant has the child's RN. In other words, you will have to make the application retroactively (up to two years back), with the application submitted later but choosing the date of administration as the start date.

In case e-Vax does not work, the antibodies should be registrated into the consultation as follows:

  • Add nirsevimab (Beyfortus) to the chronic drug list (does not require a dosage)
  • This list is part of the SumEHR and is available to other physicians
  • To be deleted after 6 months (life of antibodies)

Children under the supervision of Fedasil without a Belgian National Register number: The application can be made via medical requisitorium T7. You can leave out the fileld Belgian National Register number.

Reason for consultation: other vaccination (*44 .28)

The reimbursement of Beyfortus° for vulnerable children

The reimbursement of Beyfortus° for vulnerable children during their second season and children undergoing cardiac surgery has officially been approved. Read here the paragraph about the indications.

Extra information


Information of stakeholders

Domus Medica

Médecins généralistes francophones

ONE

KALEIDO

BCFI

Sanofi

Sciensano

Extra information

Tips to avoid stress, pain and anxiety when vaccinating young infants:

CIVARS:

Extended:

for dummies:


Advice and scientific studies

Advice

Scientific studies